上皮性卵巢癌腹膜后淋巴结复发的预后因素与治疗结局
该回顾性队列研究纳入2000至2015年单中心135例上皮性卵巢癌复发患者,按复发部位分为腹腔内、腹膜后淋巴结及两者兼有三组。腹膜后淋巴结复发组的总生存期和复发后生存期均显著优于其他两组,且为独立预后因素。
要点
- 腹膜后淋巴结复发患者的总生存期和复发后生存期显著更长。
- 腹膜后复发是生存的独立预后因素。
- 复发部位对预后有显著价值,腹膜后淋巴结复发预后良好。
核心结论
- 复发部位对复发后生存期和总生存期有显著预后价值。
- 局限于腹膜后淋巴结复发的患者预后良好,中位生存期超过5年。
研究设计与样本
- 回顾性队列研究,纳入2000至2015年单中心135例上皮性卵巢癌复发患者。
- 按复发部位分为腹腔内仅复发(66例)、腹膜后淋巴结仅复发(30例)和两者兼有(39例)三组。
- 采用RECIST标准评估治疗反应。
主要发现
- 除CA-125在诊断时、治疗结束时和复发时在腹膜后复发组显著较低外,各组临床、病理和手术特征相似。
- 中位随访45.8个月。
- 总生存期:腹膜后组93.07个月,腹腔内组47.9个月,兼有组41.7个月,p < .001。
- 复发后生存期:腹膜后组68.57个月,腹腔内组29.67个月,兼有组19.7个月,p < .001。
- Cox回归分析显示腹膜后复发是生存的独立预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the treatment outcome and survival of patients with epithelial ovarian cancer recurrence isolated to the retroperitoneal lymph nodes compared to intraperitoneal spread. METHODS: A retrospective cohort study including women with recurrence of epithelial ovarian, cancer, who were treated at a single medical center, between 2000 and 2015. Patients were classified into three groups according to the site of recurrence: intraperitoneal only, retroperitoneal lymph nodes only, and both. Response to treatment was assessed by the RECIST criteria. RESULTS: Out of 135 patients in our cohort, 66 were diagnosed with intraperitoneal recurrence, 30 with retroperitoneal lymph node recurrence and 39 with combined site recurrence. The clinical, pathological and surgical characteristics were similar among all groups, besides CA-125 which was significantly lower in the retroperitoneal recurrence group at diagnosis, end of treatment and recurrence. The median follow-up period was 45.8 months. Overall survival (OS) and post relapse survival (PRS) were significantly higher in the retroperitoneal recurrence group vs. the intraperitoneal and combined site recurrence groups. (OS - 93.07, 47.9 and 41.7 months, respectively, p < .001, PRS - 68.57, 29.67 and 19.7 months, respectively, p < .001). On cox's regression analysis, retroperitoneal recurrence was found to be an independent prognostic factor for survival. CONCLUSIONS: The site of recurrence has significant prognostic value regarding PRS and OS. Patients with recurrence limited to the retroperitoneal lymph nodes have a favourable prognosis with median survival longer than 5 years.
引用
- Levy T, Migdan Z, Aleohin N, et al. Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome. Gynecol Oncol. 2020. PMID: 32151375. doi:10.1016/j.ygyno.2020.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。